188 related articles for article (PubMed ID: 33517512)
1. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
2. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
3. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
4. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
5. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
6. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
7. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
8. Innovation as a value in healthcare priority-setting: the UK experience.
Charlton V; Rid A
Soc Justice Res; 2019; 32(2):208-238. PubMed ID: 31281204
[TBL] [Abstract][Full Text] [Related]
9. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
10. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
O'Mahony JF; Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
[TBL] [Abstract][Full Text] [Related]
11. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
12. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
13. An analysis of NICE's 'restricted' (or 'optimized') decisions.
O'Neill P; Devlin NJ
Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
[TBL] [Abstract][Full Text] [Related]
14. NICE's social value judgements about equity in health and health care.
Shah KK; Cookson R; Culyer AJ; Littlejohns P
Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
[TBL] [Abstract][Full Text] [Related]
15. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
[TBL] [Abstract][Full Text] [Related]
16. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
17. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
Dietrich ES
Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
[TBL] [Abstract][Full Text] [Related]
18. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
Charlton V; DiStefano M
BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
[TBL] [Abstract][Full Text] [Related]
19. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
[TBL] [Abstract][Full Text] [Related]
20. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
